Know Cancer

forgot password

Phase I/II Study of Lapatinib in Combination With Oral Vinorelbine for Metastatic Breast Cancer

Phase 1/Phase 2
20 Years
Open (Enrolling)
Metastatic Breast Cancer

Thank you

Trial Information

Phase I/II Study of Lapatinib in Combination With Oral Vinorelbine for Metastatic Breast Cancer

This is a phase I/II clinical trial. In phase I part, the primary objective is To determine
the recommended dose of the combination of lapatinib with oral vinorelbine in patients with
ErbB2 positive metastatic breast cancer. In phase II part, the primary objective is
progression free survival of the combination of lapatinib with oral vinorelbine as first
line chemotherapy in patients with ErbB2 positive metastatic breast cancer. The secondary
objectives are safety profile and the response rate

Lapatinib, an oral inhibitor of EGFR and HER2, have been shown to be an effective treatment
in HER2/neu overexpressing metastatic breast cancer patient who refractory herceptin,
taxane, and anthracycline treatment. In pre-clinical studies, the highest synergism between
anti-Her2 treatment (trastuzumab) and cytotoxics was seen with the platinum compounds and
with vinorelbine. The oral vinorelbine has similar efficacy to that of the injection
formulation and has demonstrated generally favorable tolerability. We are interested in
lapatinib plus oral vinorelbine as 1st line treatment in Her2+ MBC, to which we believe this
convenience treatment offer a good response rate with satisfactory life quality.

For phase I part, we plan to use the standard phase I 3-patient cohort (''3 + 3'') design.
Up to 18 patients may be enrolled. For phase II part, the expected progression-free survival
of the protocol treatment in first line treatment of ErbB2 positive metastatic breast cancer
is more than 6 months. With type 1 and type 2 errors of 0.05 and 0.1, respectively, this
design calls for 29 patients at the first stage. If 20 or more progression disease is
observed after 6 months of treatment, then the study will be terminated. Otherwise,
additional 25 patients will be entered at the second stage. The treatment will be rejected
if a total of 37 or more progression disease are observed out of 54 patients after 6 months
of treatment. With the estimated dropout rate of 10%, 32 patients will be accrued in the
first stage and 28 in the second stage.

Inclusion Criteria:

1. Histologically confirmed adenocarcinoma of the breast which is now metastatic.

2. Documented ErbB2 over expression or amplified disease in the invasive component of
the primary or metastatic lesion as defined by:

- 3+ over expression by IHC or

- ErbB2 gene amplification by FISH/CISH (> 6 ErbB2 gene copies per nucleus, or a
FISH ratio (ErbB2 gene copies to chromosome 17 signals) of > than 2.2;

3. In phase II part, patients must be chemo-naïve in metastatic setting. In phase I
part, patient may have received prior chemotherapy including vinorelbine in
metastatic setting. However, patient must be informed and well understand that in
current standard of treatment, suggested first line treatments for erbB-2 positive,
visceral organ metastatic breast cancer are combination of chemotherapy with

4. In phase II part, patient must not have exposed to ant-erbB2 targeted therapy
treatment in metastatic setting. Herceptin treatment in the neoadjuvant or adjuvant
setting is permitted provide that at least 12 months has elapsed since the last dose
of herceptin therapy. In phase I part, patient may have received prior anti-erbB-2
targeted treatment in metastatic setting.

5. Prior treatment with endocrine therapy in the adjuvant or metastatic setting
permitted provided that therapy has been discontinued.

6. Prior treatments with radiation therapy for palliative management of metastatic
disease permitted provided that at least 2 weeks have elapsed since the last fraction
of radiation therapy, disease progression has been documented and all treatment
related adverse events are < grade 1 at the time of registration.

7. Patients must have evidence of metastatic disease, but measurable disease is not
mandatory. To be considered evaluable for the overall response rate (complete and
partial response), patients must have at least one measurable lesion as follows:

- X-ray, physical exam >= 20 mm

- Conventional CT scan, MRI >= 20 mm

- Spiral CT scan >= 10 mm

8. Age > 20 years.

9. Life expectancy > 3 months.

10. ECOG PS 0-2.

11. Patients must have normal organ and marrow function measured within 14 days prior to
randomization as defined below:

- Hemoglobin>10.0;

- Absolute neutrophil count > 1,500/uL;

- Platelets >75,000/uL;

- Total bilirubin <= 1.5 X upper normal limit;

- AST(SGOT)/ALT(SGPT) <= 2.5 X upper normal limit;

- Creatinin <= 1.5 X upper normal limit;

- Patient must have cardiac ejection fraction > 50% and within the institutional
range of normal as demonstrated by MUGA scan/echocardiogram within 4 weeks of

12. CT or MRI within 4 weeks prior to randomization.

13. Women of childbearing potential must have a negative urine pregnancy test (minimum
sensitivity 25 IU/L or equivalent units of HCG) within 7 days prior to registration.

14. Patient consent must be obtained.

Exclusion Criteria:

1. Pregnant or lactating women.

2. Subjects who have current active hepatic or biliary disease (with exception of
patients with Gilbert's syndrome, asymptomatic gallstones, liver metastases or stable
chronic liver disease per investigator assessment)

3. Prior therapy with lapatinib.

4. CNS metastases.

5. Ongoing anticancer treatment.

6. Uncontrolled inter-current illness including, but not limited to, ongoing or active
infection, symptomatic congestive heart failure, uncontrolled hypertension, unstable
angina pectoris, cardiac arrhythmia, serious non-healing wound/ulcer/bone fracture,
or psychiatric illness/social situations that would limit compliance with study

7. Patients with GI tract disease resulting in an inability to take oral medication,
malabsorption syndrome, a requirement for IV alimentation, prior surgical procedures
affecting absorption, uncontrolled inflammatory GI disease (e.g., Crohn's, ulcerative

Type of Study:


Study Design:

Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment

Outcome Measure:

To determine the recommended dose of the combination of oral lapatinib with vinorelbine (phase I part), and progression free survival (phase II part)

Outcome Time Frame:

phase I part: 4 months, phase II part: 1 and half years

Safety Issue:


Principal Investigator

Yen-Shen Lu, M.D.,Ph.D

Investigator Role:

Principal Investigator

Investigator Affiliation:

Department of Oncology,National Taiwan University Hospital


Taiwan: Department of Health

Study ID:




Start Date:

May 2009

Completion Date:

December 2013

Related Keywords:

  • Metastatic Breast Cancer
  • Breast Neoplasms